Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -493.26% is 98% below its 5-year average of -249.42%, around the middle of its 5-year range (-1485.07%–83.24%).
39.60% above its 12-month average of -816.62%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -683.42%.
NET PROFIT MARGIN
-493.26%
NET PROFIT MARGIN AVG TTM
-816.62%
NET PROFIT MARGIN AVG 3Y
-389.19%
NET PROFIT MARGIN AVG 5Y
-249.42%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+39.60%
CURRENT VS 3Y AVG
-26.74%
CURRENT VS 5Y AVG
-97.76%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 563 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Immatics N.V.
Market Cap
$1.01B
Net Profit Margin
-493.26%
TTM Avg
-816.62%
3Y Avg
-389.19%
5Y Avg
-249.42%
Market Cap
$997.09M
Net Profit Margin
-321.81%
TTM Avg
-893.93%
3Y Avg
-810.32%
5Y Avg
-689.93%
Market Cap
$1.00B
Net Profit Margin
-0.44%
TTM Avg
-16.00%
3Y Avg
-4.01%
5Y Avg
0.78%
Market Cap
$990.92M
Net Profit Margin
19.87%
TTM Avg
-292.21%
3Y Avg
-499.51%
5Y Avg
-430.28%
Market Cap
$996.93M
Net Profit Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.03B
Net Profit Margin
-2.66%
TTM Avg
-7.26%
3Y Avg
-9.19%
5Y Avg
-9.19%
Market Cap
$987.02M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-57.69%
Market Cap
$989.06M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.04B
Net Profit Margin
-7.13%
TTM Avg
-23.45%
3Y Avg
-155.72%
5Y Avg
-114.72%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immatics N.V. (IMTX) | $1.01B | -493.26% | -816.62% | -389.19% | -249.42% |
| Janux Therapeutics, Inc. (JANX)vs › | $997.09M | -321.81% | -893.93% | -810.32% | -689.93% |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.00B | -0.44% | -16.00% | -4.01% | 0.78% |
| MeiraGTx Holdings plc (MGTX)vs › | $990.92M | 19.87% | -292.21% | -499.51% | -430.28% |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $996.93M | N/A | N/A | N/A | N/A |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.03B | -2.66% | -7.26% | -9.19% | -9.19% |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $987.02M | 0.00% | 0.00% | 0.00% | -57.69% |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $989.06M | 0.00% | 0.00% | 0.00% | 0.00% |
| Teladoc Health, Inc. (TDOC)vs › | $1.04B | -7.13% | -23.45% | -155.72% | -114.72% |
| Aktis Oncology, Inc. (AKTS)vs › | $971.43M | -727.04% | -1969.28% | -984.64% | -984.64% |
Operating Margin
-377.1%
Net Profit Margin
-493.3%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -683.42% |
| 2026-03-31 | -759.51% |
| 2025-12-31 | -180.65% |
| 2025-09-30 | -974.46% |
| 2025-06-30 | -1485.07% |
| 2025-03-31 | -214.48% |
| 2024-12-31 | 79.75% |
| 2024-09-30 | -16.95% |
| 2024-06-30 | -95.93% |
| 2024-03-31 | -7.40% |
| 2023-12-31 | -164.24% |
| 2023-09-30 | -447.00% |
| 2023-06-30 | -110.09% |
| 2023-03-31 | -201.58% |
| 2022-12-31 | -35.15% |
| 2022-09-30 | -139.01% |
| 2022-06-30 | -81.21% |
| 2022-03-31 | 83.24% |
| 2021-12-31 | -106.74% |
| 2021-09-30 | -422.21% |
| 2021-06-30 | -511.35% |
| 2021-03-31 | -308.16% |
| 2020-12-31 | -190.24% |
| 2020-09-30 | -2083.04% |
| 2020-06-30 | -305.15% |
| 2020-03-31 | -117.98% |
| 2019-12-31 | -335.58% |
| 2019-09-30 | -93.18% |
| 2019-06-30 | -120.04% |
| 2019-03-31 | -156.76% |
| 2018-12-31 | -779.15% |
| 2018-09-30 | -779.15% |
| 2018-06-30 | -779.15% |
| 2018-03-31 | -779.15% |
